Risks and benefits of reducing the number of drugs to treat HIV-1 infection

References

• European AIDS clinical society guidelines[Internet]. [cited 2020 Oct 12]. Available from: https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
   Google Scholar
• Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA. 2020;320:379–396.
   Web of Science ®Google Scholar
• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – a Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. [cited 2020 Oct 12]. Available from: https://clinicalinfo.hiv.gov/es/guidelines.
   Google Scholar
• Kozal MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13:119–130.
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–265.
   PubMed Web of Science ®Google Scholar
• De Lazzari E, Lonca M, Rojas J, et al. A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine. Aids. 2019;33:1891–1896.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Capetti A, Rizzardini G. Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opin Drug Metab Toxicol. 2019;15:245–252.
   PubMed Web of Science ®Google Scholar
• Trottier B, Galanakis C, Longpre D, et al. Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). HIV Clin Trials. 2015;16:111–116.
   PubMed Web of Science ®Google Scholar
• Davis W, Mantsios A, Karver T, et al. “It made me more confident that I have it under control”: patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. PLoS One. 2020;15:e0232473.
   PubMed Web of Science ®Google Scholar
• Borghetti A, Lombardi F, Gagliardini R, et al. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice 11. BMC Infect Dis. 2019;19:1–9.
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716–723.
   PubMed Web of Science ®Google Scholar
• Heron JE, Bagnis CI, Gracey DM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther. 2020;17:1–13.
   PubMed Web of Science ®Google Scholar
• Warriner AH, Mugavero M, Overton ET. Bone alterations associated with HIV. Curr HIV/AIDS Rep. 2014;11:233–240.
   PubMed Web of Science ®Google Scholar
• Hill A, Hughes SL, Gotham D, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4:72–79.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment. JAIDS. 2016;71:530–537.
   Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Hagins D, Orkin C, Daar ES, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19:724–733.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ. Lancet HIV. 2016;3:e158–e165.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379–1389.
   PubMed Web of Science ®Google Scholar
• Pilkington V, Hughes SL, Pepperrell T, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34:2259–2268.
   PubMed Web of Science ®Google Scholar
• Dorjee K, Baxi SM, Reingold AL, et al. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017;17:708.
   PubMed Web of Science ®Google Scholar
• Li JZ, Sax PE, Marconi VC, et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infect Dis. 2019;6:5–8.
   Web of Science ®Google Scholar
• Gutierrez M, Mateo MG, Vidal F, et al. Does choice of antiretroviral drugs matter for inflammation? Expert Rev Clin Pharmacol. 2019;12:389–396.
   PubMed Web of Science ®Google Scholar
• Vallejo A, Molano MC, Monsalvo-Hernando M, et al. Switching to dual antiretroviral regimens is associated with improvement or no changes in activation and inflammation markers in virologically suppressed HIV-1-infected patients: the TRILOBITHE pilot study. HIV Med. 2019;20:555–560.
   PubMed Web of Science ®Google Scholar
• Trunfio M, Rugge W, Mighetto L, et al. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. AIDS. 2020;34:1899–1906.
   PubMed Web of Science ®Google Scholar
• Gay CL, Neo DT, Devanathan AS, et al. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. AIDS. 2020;34:1923–1931.
   PubMed Web of Science ®Google Scholar
• Arendt G, Schlonies S, Orhan E, et al. Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience. J Neurovirol. 2019;25:174–182.
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Lia Gubavu C, Prazuck T, et al. Genital human immunodeficiency virus-1 RNA and DNA shedding in virologically suppressed individuals switching from triple-to dual-or monotherapy: pooled results from 2 randomized, controlled trials. Clin Infect Dis. 2020;70:1973–1979.
   PubMed Web of Science ®Google Scholar
• Gianella S, Marconi VC, Berzins B, et al. Genital HIV-1 shedding with Dolutegravir (DTG) plus lamivudine (3TC) dual therapy. JAIDS. 2018;79:e112–e114.
   Google Scholar
• Rolón MJ. Dual therapy with Lopinavir/Ritonavir (LPV/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in naïve HIV-1 infected subjects: 96-week results of the GARDEL Study. Exhibited at the 15th European AIDS Conference. 21-24 October 2015, Barcelona (Spain). Abstract PS10/4.
   Google Scholar
• Figueroa MI, Sued OG, Gun AM. et al. DRV/R FDC plus 3TC for HIV-1 treatment naive patients: week 48 results of the ANDES study. Exhibited atthe Conference on Retroviruses and Opportunistic Infections. March 4-7 2018, Boston, Massachusetts (United States). Abstract 489.
   Google Scholar
• Stellbrink HJ, Le Fevre E, Carr A, et al. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. Aids. 2016;30:1229–1238.
   PubMed Web of Science ®Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–1951.
   PubMed Web of Science ®Google Scholar
• Cahn P, Sierra J, Arribas JR, et al. Durable efficacy of Dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection - 3 year results from the GEMINI studies. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract P018.
   Google Scholar
• Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results. Exhibited at the Conference on Retroviruses and Opportunistic Infections. March 8-11 2020, Boston, Massachusetts (United States). Abstract 482.
   Google Scholar
• D’Amico R, Orkin C, Bernal Morell E. et al. Safety and efficacy of cabotegravir + rilpivirine long-acting with and without oral lead‐in: FLAIR Week 124 results. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract O414.
   Google Scholar
• Molina J-M, Yazdanpanah Y, Afani Saud A, et al. Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract O415.
   Google Scholar
• Randomized, double-blind, efficacy, and safety study of doravirine/islatravir (DOR/ISL) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection (MK-8591A-020) [Internet]. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04233879.
   Google Scholar
• Perez-Molina JA, Rubio R, Rivero A, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother. 2017;72:246–253.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018;73:1955–1964.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard P-M, Landman R, et al. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:785–792.
   PubMed Web of Science ®Google Scholar
• Pulido F, Ribera E, Lagarde M, et al. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial. Clin Infect Dis. 2017;65:2112–2118.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Gianotti N, Comi L, et al. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). J Antimicrob Chemother. 2020;75:1332–1337.
   PubMed Web of Science ®Google Scholar
• Di Cristo V, Adorni F, Maserati R, et al. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation. HIV Res Clin Pract. 2020;21:34–43.
   PubMed Web of Science ®Google Scholar
• Pett SL, Amin J, Horban A, et al. Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first nucleoside/nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: week 48 results of the randomized, multicenter MARCH study. Clin Infect Dis. 2016;63:122–132.
   PubMed Web of Science ®Google Scholar
• Rossetti B, Gagliardini R, Meini G, et al. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial. PLoS One. 2017;12:1–18.
   Web of Science ®Google Scholar
• Ofotokun I, Sheth AN, Sanford SE, et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses. 2012;28:1196–1206.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Shimbo T, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013;8:1–10.
   Web of Science ®Google Scholar
• Spinner CD, Kümmerle T, Schneider J, et al. Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1: a randomized, open-label, multicenter, phase 3, non-inferiority trial: the DUALIS study. Open Forum Infect Dis. 2020. Available online 13 August 2020. DOI: 10.1093/ofid/ofaa356
   PubMed Web of Science ®Google Scholar
• van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract O441.
   Google Scholar
• Regimen switch to dolutegravir/lamivudine fixed dose combination from current antiretroviral regimen in HIV-1 infected and virologically suppressed adults (SALSA) [Internet]. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04021290.
   Google Scholar
• van Wyk J, Orkin C, Rubio R, et al. Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. JAIDS J Acquir Immune Defic Syndr. 2020;85:325–330.
   PubMed Web of Science ®Google Scholar
• Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112–1123.
   PubMed Web of Science ®Google Scholar
• Swindells S, Lutz T, Van Zyl L, et al. Cabotegravir + rilpivirine long-acting as HIV‐1 maintenance therapy: ATLAS Week 96 results. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract P006.
   Google Scholar
• Overton ET, Richmond GJ, Rizzardini G. et al. Cabotegravir + Rilpivirine every 2 months is noninferior to monthly: ATLAS-2M STUDY. Exhibited at the Conference on Retroviruses and Opportunistic Infections. March 8-11 2020, Boston, Massachusetts (United States). Abstract 34.
   Google Scholar
• Safety and efficacy of a switch to doravirine/islatravir in participants with HIV-1 (MK-8591A-017) [Internet]. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04223778.
   Google Scholar
• Switch to doravirine/islatravir (DOR/ISL) in human immunodeficiency virus 1 (HIV-1) participants treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) (MK-8591A-018) [Internet]. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04223791.
   Google Scholar
• Doravirine/Islatravir (DOR/ISL) in heavily treatment-experienced (HTE) participants for human immunodeficiency virus type 1 (HIV-1) Infection (MK-8591A-019) [Internet]. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04233216.
   Google Scholar
• Dose ranging, switch study of islatravir (ISL) and MK-8507 once-weekly in virologically-suppressed adults with human immunodeficiency virus type 1 (HIV-1) [MK-8591-013] [Internet]. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04564547.
   Google Scholar
• WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV [Internet]. [cited 2020 Oct 12]. Available from: https://www.who.int/publications/guidelines/hiv_aids/en/.
   Google Scholar
• Dovato. EPAR - product information. Eur Med Agency [Internet]. [cited 2020 Oct 12]. Available from: https://www.ema.europa.eu/en/documents/productinformation/dovato-epar-product-information_en.pdf
   Google Scholar
• DOVATO. FDA approval labeling. US Food Drug Adm [Internet]. [cited 2020 Oct 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211994Orig1s000Lbl.pdf
   Google Scholar
• Rolle C, Berhe M, Singh T. et al. Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first‐line regimen in a test‐and‐treat setting for newly diagnosed PLWH: the STAT study. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October, 2020, Glasgow (United Kingdom). Abstract P020.
   Google Scholar
• Triant VA, Siedner MJ. Darunavir and cardiovascular risk: evaluating the data to inform clinical care. J Infect Dis. 2020;221:498–500.
   PubMed Web of Science ®Google Scholar
• Lee SA, Kim SW, Chang HH, et al. Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus. Infect Chemother. 2018;50:252–262.
   PubMed Web of Science ®Google Scholar
• Tseng A, Hughes CA, Wu J, et al. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51:1008–1022.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Pulido F, Di Giambenedetto S, et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: geSIDA study 9717. J Antimicrob Chemother. 2018;73:2927–2935.
   PubMed Web of Science ®Google Scholar
• Belmonti S, Lombardi F, Quiros-Roldan E, et al. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018;73:1949–1954.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Quiros-Roldan E, et al. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother. 2017;72:2055–2059.
   PubMed Web of Science ®Google Scholar
• Pérez-Valero I, Pasquau J, Rubio R, et al. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. J Antimicrob Chemother. 2018;73:2444–2451.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Valencia A, García C, Viciana P, et al. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients. PLoS One. 2018;13:2–13.
   Web of Science ®Google Scholar
• Kheloufi F, Boucherie Q, Blin O, et al. Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect. Aids. 2017;31:1775–1777.
   PubMed Web of Science ®Google Scholar
• Zash R, Holmes L, Diseko M. et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Exhibited at the International AIDS Conference. July 6-10, 2020, Virtual. Abstract OAXLB0102.
   Google Scholar
• Casado JL, Monsalvo M, Fontecha M, et al. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. HIV Res Clin Pract. 2019;20:64–72.
   PubMedGoogle Scholar
• Galizzi N, Poli A, Galli L, et al. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. Int J Antimicrob Agents. 2020;55:105893.
   PubMed Web of Science ®Google Scholar
• Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2015;62:784–791.
   PubMed Web of Science ®Google Scholar
• Gillman J, Janulis P, Gulick R, et al. Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. J Antimicrob Chemother. 2019;74:2365–2369.
   PubMed Web of Science ®Google Scholar
• Eron J, Hung CC, Baril JG, et al. Brief report: virologic response by baseline viral load with dolutegravir plus lamivudine vs dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis. J Acquir Immune Defic Syndr. 2020;84:60–65.
   PubMed Web of Science ®Google Scholar
• Diaco ND, Strickler C, Giezendanner S, et al. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons. EClinicalMedicine. 2018;6:21–25.
   PubMedGoogle Scholar
• Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66:1794–1797.
   PubMed Web of Science ®Google Scholar
• Radford M, Parks DC, Ferrante S, et al. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. Aids. 2019;33:1739–1749.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Cossu MV, et al. Dolutegravir plus lamivudine as first-line regimen in a multicenter cohort of HIV-1-infected patients: preliminary data from clinical practice. AIDS Res Hum Retroviruses. 2020;36:4–5.
   PubMed Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Rusconi S, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54:728–734.
   PubMed Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Borghetti A, et al. Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019;74:1461–1463.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection. Drugs. 2020;80:61–72.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, D’avino A, Lassandro AP, et al. Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. Infez Med. 2018;26:336–340.
   PubMedGoogle Scholar
• Borghetti A, Baldin G, Ciccullo A, et al. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. J Antimicrob Chemother. 2016;71:2359–2361.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Dusina A, Lassandro AP, et al. No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine–dolutegravir. AIDS. 2020;34:956–957.
   PubMed Web of Science ®Google Scholar
• Taiwo BO, Quiñones-Mateu ME, Smith K, et al. Prior case of resistance on dolutegravir plus lamivudine dual therapy. AIDS Res Hum Retroviruses. 2020;36:254–255.
   PubMed Web of Science ®Google Scholar
• Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis. 2018;5:1–8.
   Web of Science ®Google Scholar
• Reynes J, Montes B, Tuaillon E, et al. Virological efficacy and tolerability of dual therapy maintenance with dolutegravir plus lamivudine in heavily treatment experienced HIV-infected patients: four years data from DOLULAM study. Exhibited at the International AIDS Conference. July 6-10 2020, Virtual. Abstract PEB0241.
   Google Scholar
• de Miguel R, Rial D, Domínguez-Domínguez L. et al. Long-term DTG-3TC switch efficacy in patients with archived 3TC resistance. Exhibited at the Conference on Retroviruses and Opportunistic Infections. March 8-11 2018, Boston, Massachusetts (United States). Abstract 485. 
   Google Scholar
• Oliveira M, Ibanescu RI, Pham HT, et al. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. Aids. 2016;30:2267–2273.
   PubMed Web of Science ®Google Scholar
• Giacomelli A, Lai A, Franzetti M, et al. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: time of viral suppression makes the difference. Antiviral Res. 2019;172:104635.
   PubMed Web of Science ®Google Scholar
• Ward AR, Mota TM, Jones RB. Immunological approaches to HIV cure. Semin Immunol. 2020. Available online 24 September 2020. DOI: 10.1016/j.smim.2020.101412
   PubMedGoogle Scholar